Free tool
FAERS Monitor: Subvenite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218879 or its brand name (Subvenite, Lamotrigine). Reports on generic versions are filed under their own applications.
Reports
72,862
Serious
58,992
81% of reports
Hospitalization
24,162
Death reported
8,331
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6,370
- seizure4,360
- toxicity to various agents4,055
- off label use3,588
- drug interaction3,308
- completed suicide3,096
- fatigue3,078
- dizziness3,048
- nausea3,032
- rash2,950
- foetal exposure during pregnancy2,803
- headache2,763
- somnolence2,630
- depression2,460
- vomiting2,396
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 292 |
| 2005 | 396 |
| 2006 | 458 |
| 2007 | 474 |
| 2008 | 887 |
| 2009 | 1,569 |
| 2010 | 1,591 |
| 2011 | 1,999 |
| 2012 | 2,158 |
| 2013 | 2,064 |
| 2014 | 2,256 |
| 2015 | 3,089 |
| 2016 | 3,716 |
| 2017 | 4,244 |
| 2018 | 5,236 |
| 2019 | 5,717 |
| 2020 | 5,532 |
| 2021 | 5,352 |
| 2022 | 4,967 |
| 2023 | 5,236 |
| 2024 | 5,638 |
| 2025 | 5,668 |
| 2026 | 4,322 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,981,297 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 4,360 | 11.3 | 11.0 | 39,531 |
| completed suicideSignal | 3,096 | 11.1 | 10.7 | 27,495 |
| foetal exposure during pregnancySignal | 2,803 | 10.3 | 9.9 | 22,734 |
| toxicity to various agentsSignal | 4,055 | 7.1 | 6.9 | 20,853 |
| drug interactionSignal | 3,308 | 6.1 | 5.9 | 13,994 |
| somnolenceSignal | 2,630 | 3.8 | 3.7 | 5,421 |
| depressionSignal | 2,460 | 3.1 | 3.0 | 3,595 |
| rash | 2,950 | 2.0 | 1.9 | 1,406 |
| dizziness | 3,048 | 1.8 | 1.7 | 1,036 |
| vomiting | 2,396 | 1.5 | 1.4 | 370 |
| drug ineffective | 6,370 | 1.4 | 1.4 | 763 |
| headache | 2,763 | 1.3 | 1.2 | 166 |
| off label use | 3,588 | 1.2 | 1.1 | 106 |
| fatigue | 3,078 | 1.1 | 1.1 | 56 |
| nausea | 3,032 | 1.1 | 1.1 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.